The emerging role of cytokines in the treatment of advanced melanoma

Oncology

Volumn 58, Issue 2, 2000, Pages 89-95

  Keilholz, Ulrich ^b   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Chemo immunotherapy; EORTC; Interferon ; Interleukin 2; Melanoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOKINE; INTERLEUKIN 2;

ADVANCED CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNOTHERAPY; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0034000545     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012085     Document Type: Review

References (51)

1. Seigler HF, Lucas VS, Picett NJ, Huang AT: DTIC, CCNU, bleomycin, and vincristine (BOLD) in metastatic melanoma. Cancer 1980;46:2346-2348.
2. Legha S: Current therapy for malignat melanoma. Semin Oncol 1989;16:34-44.
3. Lakkhani S, Selby P, Bliss JM, Perren TJ, Gore ME, McElwain TJ: Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit. Br J Cancer 1990;61:330-334.
4. Balch CM: Cutaneous melanoma: Prognosis and treatment results worldwide. Semin Surg Oncol 1992;8:400-414.
5. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992;327:516-523.
6. Falkson CL, Falkson G, Falkson HC: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991;9:1403-1408.
7. Falkson CL, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH: Phase III trial of dacarbazine versus dacarbazine with interferon-alfa2b versus dacarbazine with tamoxifen versus dacarbazine with interferon-alfa2b and tamoxifen in patients with metastatic malignant melanoma: An ECOG study. J Clin Oncol 1998;16:1743-1751.
8. Thompson DB, Adena M, McLeod GR, et al: Interferon-alfa 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: Results of a multi-institutional Australian trial. Melanoma Res 1993;3:133-138.
9. Bajetta E, Di Leo A, Zampino MG, et al: Multicenter randomized trial of dacarbazine alone or in combination of two different doses and schedules of Interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994;12: 806-811.
10. Rusthoven JJ, Quirt IC, Iscoe NA, et al: Randomized, double-blind, placebo controlled trial comparing the response rates of carmustinc, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 1996;14:2083-2090.
11. Kirkwood JM: Studies of interferons in the therapy of melanoma. Semin Oncol 1991;18: 83-90.
12. Rosenberg SA, Lotze MT, Yang JC, Abersold JC, Linehan WM, Seipp C, et al: Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-485.
13. Thatcher N, Dazzi H, Gosh A, Johnson RJ: Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: A phase I/II study. Cancer Treat Rev 1989; 16(suppl A):49-52.
14. Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, et al: Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 1990;8: 1650-1656.
15. Whitehead RP, Kopecky KJ, Samson MK, Constanzi JJ, Natale RB, et al: Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. J Natl Cancer Inst 1991;83:1250-1251.
16. Dorval T, Mathiot C, Brandely M, Escande MC, Fridman WH, et al: Lack of effect of tumour infiltrating lymphocytes in patients with metastatic melanoma who failed to respond to interleukin 2. Correspondence. Eur J Cancer 1991;27(suppl 2):S99.
17. Sparano JA, Fisher RI, Sunderland M, et al: Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon-alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11:1969-1977.
18. Legha SS, Gianan MA, Plager C, Eton Œ, Papadopoulos NEJ: Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996; 77:89-96.
19. Giacomini P, Aguzzi A, Pestka S, et al: Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA and tumor-associated antigens by human melanoma cells. J Immunol 1984;133:1649-1655.
20. Zoller M: IFN-treatment of B166-F1 versus B16-F10: Relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread. Clin Exp Metastasis 1988;6:411-429.
21. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
22. Kruit WHJ, Punt CJA, Goey SH, de Mulder PHM, Gratama JW, Eggermont AMM, Bolhuis RLH, Stoter G: Dose-efficacy study of two schedules of high-dose bolus administration of interleukin-2 and alpha-interferon in patients with metastatic melanoma. Br J Cancer 1996; 74:951-955.
23. Keilholz U, Scheibenbogen C, Sommer M, Pritsch M, Geueke AM: Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy. Melanoma Res 1996;6:173-178.
24. West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thurman GB, et al: Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
25. Kruit WH, Goey SH, Monson JR, Stahel RA, Calabresi R, et al: Clinical experience with the combined use of recombinant interleukin-2 (IL-2) and interteron-2a (IFN alpha) in metastatic melanoma. Br J Haematol 1991;79(suppl 1):84-86.
26. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, Richter M, Brado B, Mitrou PS, Hunstein W: Interferon-a and interleukin-2 in the treatment of malignant melanoma: A comparison of two phase II trials. Cancer 1993;72:607-614.
27. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, et al: Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993;71:2358-2370.
28. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, et al: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-1874.
29. Marincola FM, White DE, Wise AP, Rosenberg SA: Combination therapy with Interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995;5:1110-1122.
30. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock J, Fritsch P. Kerl H, Wolff K: Adjuvant interferon alfa-2a in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16: 1425-1429.
31. Grob JJ, Dreno B, de la Salmoniere P, Delauny M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ: Randomized trial of interferon alfa-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905-1910.
32. Cascinelli N, Bufalino R, Morabito A, Mackie R: Results of adjuvant interferon melanoma study in WHO melanoma programme. Lancet 1994;343:913-914.
33. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
34. Stoter G, Shiloni E, Aamdal S, Cleton FJ, Iacobelli S, et al: Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study. Eur J Cancer Clin Oncol 1989; 25(suppl 3):41-43.
35. Dillman RO, Oldham RK, Barth NM, Birch R, Arnold J, et al: Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarhazine therapy in melanoma: A National Biotherapy Study Group trial. J Natl Cancer Inst 1990;82:1345-1349.
36. Flaherty LE, Redman BG, Chabot GG, Martino S, Gualdoni SM, et al: A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 1990;65:2471-2477.
37. Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, ed al: Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study. J Clin Oncol 1991;9:1821-1830.
38. Flaherty LE, Robinson W, Redman BG, Gonzalez DR, Martino S, Kraut M, Valdivieso M. Rudolph AR: A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993;71:3520-3525.
39. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, et al: Multiinstitutional phase II trial of intensive combination chemotherapy for metastatic melanoma. J Clin Oncol 1994;12:1553-1560.
40. Dummer R, Gore ME, Hancock BW, Guillou PJ, Grobben HC, Becker JC, et al: A multi-center phase II clinical trial using dacarhazine and continuous infusion of interleukin-2 in metastatic melanoma: Clinical data and immunomonitoring. Cancer 1995;75:945-948.
41. Richards JM, Mehta N, Ramming K, Skosey P: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-1343.
42. Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, Vuillemin E, Bazex PA, Thill L, Franks R, Auclerc G, Soubrane C, Banzet P, Weil M: Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2 for metaslatic melanoma. J Clin Oncol 1993;11:2173-2180.
43. Buzaid AC, Legha SS: Combination of chemotherapy with interleukin-2 and interferon-alpha for the treatment of advanced melanoma. Semin Oncol 1994;6(suppl 14):23-28.
44. Proebstle ThM, Keilholz U, Scheibenbogen C, Sterry W, Hunstein W: A phase II study of DTIC, CDDP, interferon-α, and high dose IL-2 in 'poor risk' metastatic melanoma. Eur J Cancer 1996;32:1530-1533.
45. Redman BG, Flaherty L, Chou TH, Nakeff A, Pillote K, Kaplan J: Sequential dacarbazine/ cisplatin and interleukin-2 in metastatic melanoma: Immunological effects of therapy. J Immunother 1991;10:147-151.
46. Keilholz U, Scheibenbogen C, Möhler T, Brossart P, Geueke AM, Jochim A, Hunstein W: Addition of dacarbazine or cisplatin to IFNa/ IL-2 in metastatic melanoma: Toxicity and immunological effects. Melanoma Res 1995;5: 283-287.
47. Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996;7:827-835.
48. Keilholz U, Conradt C, Legha S, Khayat D, Scheibenbogen C, Thatcher N, Goey SH, Gore M. Dorval T, Hancock B, Punt CJA, Dummer R, Avril MF, Bröcker EB, Benhammouda A, Eggermont AMM, Pritsch M: Results of IL-2-based treatment in advanced melanoma: A case-record based analysis of 631 patients. J Clin Oncol 1998;16:1921-1926.
49. Keilholz U, Goey SH, Punt CJA, et al: IFN-α and IL-2 with or without cisplatin in metastatic melanoma: A randomized trial of the EORTC Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-2588.
50. Johnston SRD, Constenla DO, Moore J, Atkinson H, A'Hern RP, Dadian G, Riches PG, Gore ME: Randomized phase II trial of BCDT with or without interferon alpha and interleukin-2 in patients with metastatic melanoma. Br J Cancer 1998;77:1280-1286.
51. Hauschild A, Garbe C, Dummer R, Tilgen W: Dacarbazine plus interferon-a with and without interleukin-2 in advanced melanoma: A German/Swiss phase III multicenter trial. Proc ASCO 1998;17:516a.